<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="758">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01954251</url>
  </required_header>
  <id_info>
    <org_study_id>117036</org_study_id>
    <secondary_id>2013-000372-15</secondary_id>
    <nct_id>NCT01954251</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older</brief_title>
  <official_title>Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Germany: German Federal Ministry of Health</authority>
    <authority>Canada: Health Canada</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess immunogenicity, reactogenicity and safety of GSK
      Biologicals' HZ/su vaccine when its first dose is co-administered with the FLU-D-QIV vaccine
      in adults aged 50 years or older compared to administration of vaccines separately.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Number of Subjects With Vaccine Response to Anti-gE Antibodies</measure>
    <time_frame>At one month post-dose 2 (Month 3)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The vaccine response(VRR) for anti-gE humoral immunogenicity, as determined by enzyme-linked immunosorbent assay (ELISA),was assessed only in subjects from the GSK1437173A + GSK2321138A Group. The VRR for anti-gE was defined as the percentage of subjects who had at least: a 4-fold increase in the post-dose 2 anti-gE antibody concentration as compared to the pre-vaccination anti-gE antibody concentration, for subjects who were seropositive at baseline (cut-off ≥ 97 mIU/ml), or, a 4-fold increase in the post dose 2 anti-gE antibody concentrations as compared to the anti-gE antibodies cut-off value for seropositivity, for subjects who were seronegative at baseline (cut-off &lt; 97 mIU/ml).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vaccine Response for Anti-gE Humoral Immunogenicity</measure>
    <time_frame>At one month post-dose 2 (Month 3)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The vaccine response(VRR) for anti-gE humoral immunogenicity, as determined by enzyme-linked immunosorbent assay (ELISA),was assessed only in subjects from the GSK1437173A + GSK2321138A Group. The VRR for anti-gE was defined as the percentage of subjects who had at least:
a 4-fold increase in the post-dose 2 anti-gE antibody concentration as compared to the pre-vaccination anti-gE antibody concentration, for subjects who were seropositive at baseline (cut-off ≥ 97 mIU/ml), or, a 4-fold increase in the post dose 2 anti-gE antibody concentrations as compared to the anti-gE antibodies cut-off value for seropositivity, for subjects who were seronegative at baseline (cut-off &lt; 97 mIU/ml).Criterion used: the objective was met if the Lower Limit (LL) of the 95% confidence interval (CI) of the VRR for anti-gE antibody concentrations was at least 60%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adjusted Geometric Mean ELISA Concentrations of Anti-gE Antibodies</measure>
    <time_frame>At one month post-dose 2 (Month 3 for GSK1437173A + GSK2321138A group and Month 5 for Control group)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Geometric means (GMs) of post-vaccination concentrations (Month 3 for GSK1437173A + GSK2321138A group and Month 5 for Control group) was calculated conditionally to the means of the pre-vaccination log-transformed concentrations for anti-gE (Month 0 for GSK1437173A + GSK2321138A group and Month 2 for Control group). Adjusted Least Squares (LS) means and difference of LS means between the groups were calculated together with 2-sided 95% CIs and back-transformed to the original units to provide GMCs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FLU Haemagglutination Inhibition (HI) Antibodies Titers</measure>
    <time_frame>At Day 21 post vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>For each strain included in the FLU-D-QIV vaccine, an ANOVA model was used to analyze post-vaccination log-transformed titers. The fixed-effect model included the minimization variable (age cohorts) and the treatment as fixed effect. The pre-vaccination log-transformed concentrations were included as continuous covariate. Geometric Means (GM) of post-vaccination titers (Day 21) were calculated conditionally to the means of the pre-vaccination log-transformed titers (Month 0) for each strain.
Adjusted GMTs (GMTs adjusted for baseline titers) and Adjusted GMT ratios were calculated together with 2-sided 95% CIs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With FLU HI Antibodies ≥1:10</measure>
    <time_frame>At Days 0 and 21 post vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>FLU HI antibodies were assessed in four strains: Flu A/California/7/2009 H1N1, Flu A/Victoria/361/2011 H3N2, Flu B/Brisbane/60/2008 Victoria and Flu B/Massachusetts/2/2012 Yamagata (Yamag). Cut-off titer for seropositivity was 1:10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected Subjects With HI Antibody Concentrations ≥ 1:40</measure>
    <time_frame>At Day 0 (PRE) and at Day 21 post vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seroprotection rate is defined as the percentage of vaccines with a serum HI titer ≥1:40 that usually was accepted as indicating protection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FLU Haemagglutination Inhibition (HI) Antibody Titers</measure>
    <time_frame>At Day 0 (PRE) and Day 21 post vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>HI antibody titres against the four influenza vaccine strains Flu A/California/7/2009, Flu A/Victoria/361/2011, Flu B/Brisbane/60/2008 Victoria and Flu B/Massachusetts/2/2012 Yamagata were expressed as geometric mean titers (GMTs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroconverted Subjects in Terms of HI Antibodies</measure>
    <time_frame>At Day 21 post vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of seroconverted subjects was assessed in terms of HI antibodies against the four influenza vaccine strains Flu A/California/7/2009, Flu A/Victoria/361/2011, Flu B/Brisbane/60/2008 Victoria and Flu B/Massachusetts/2/2012 Yamagata.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Ratio for Flu HI Antibodies Post-vaccination Titer</measure>
    <time_frame>At Day 21 post vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>The geometric mean ratio for Flu HI antibodies against the four influenza vaccine strains Flu A/California/7/2009, Flu A/Victoria/361/2011, Flu B/Brisbane/60/2008 Victoria and Flu B/Massachusetts/2/2012 Yamagata was defined as the geometric mean of the within subject ratios of the post-vaccination reciprocal HI titer to the Day 0 reciprocal HI titer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Solicited Local Symptoms</measure>
    <time_frame>Within 7 days (Days 0-6) after each vaccine dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. Relationship analysis was not performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Solicited Local Symptoms</measure>
    <time_frame>Within 7 days (Days 0-6) after each vaccine dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. Relationship analysis was not performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Solicited General Symptoms</measure>
    <time_frame>Within 7 days (Days 0-6) after each vaccine dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed solicited general symptoms were arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Unsolicited Adverse Events (AEs)</measure>
    <time_frame>During 30 days (Days 0-29) after vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Serious Adverse Events (SAEs)</measure>
    <time_frame>From first vaccination up to Month 18 (study end)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Potential Immune-mediated Diseases (pIMDs)</measure>
    <time_frame>From first vaccination up to Month 18 (study end)</time_frame>
    <safety_issue>No</safety_issue>
    <description>pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">829</enrollment>
  <condition>Herpes Zoster</condition>
  <arm_group>
    <arm_group_label>Co-Ad Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects assigned to the Co-Ad group will receive one injection of the FLU-D-QIV vaccine and one injection of the HZ/su study vaccine during the first visit and a second injection of the HZ/su study vaccine during the third visit, two months later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The subjects assigned to the Control group will receive all vaccines separately: one injection of the FLU-D-QIV vaccine at the first visit, one injection of the HZ/su study vaccine at the third visit and a second injection of the HZ/su study vaccine at the fourth visit, all two months apart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Herpes Zoster vaccine GSK 1437173A</intervention_name>
    <description>2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Co-Ad Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A</intervention_name>
    <description>2 doses administered intramuscularly (IM) in the deltoid region of the dominant arm.</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Co-Ad Group</arm_group_label>
    <other_name>Influsplit™ Tetra (Germany)</other_name>
    <other_name>Fluarix™ Quadrivalent (United States)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who, in the opinion of the investigator, can and will comply with the
             requirements of the protocol (e.g. completion of the diary cards, return for
             follow-up visits).

          -  A male or female aged 50 years or older, at the time of the first vaccination with
             the study vaccine(s).

          -  Written informed consent obtained from the subject.

          -  Female subjects of non-childbearing potential may be enrolled in the study.

               -  Non-childbearing potential is defined as pre-menarche, current tubal ligation,
                  hysterectomy, ovariectomy or post-menopause.

          -  Female subjects of childbearing potential may be enrolled in the study, if the
             subject:

               -  has practiced adequate contraception for 30 days prior to vaccination, and

               -  has a negative pregnancy test on the day of vaccination, and

               -  has agreed to continue adequate contraception during the entire treatment period
                  and for 2 months after completion of the vaccination series.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccines within 30 days preceding the first dose of study vaccine, or planned
             use during the study period.

          -  Chronic administration (defined as more than 14 consecutive days) of
             immunosuppressants or other immune-modifying drugs within six months prior to the
             first vaccine dose (for corticosteroids, this will mean prednisone ≥ 20 mg/day, or
             equivalent). A prednisone dose of &lt; 20 mg/day is allowed. Inhaled, topical and
             intra-articular corticosteroids are allowed.

          -  Administration or planned administration of a vaccine not foreseen by the study
             protocol within the period starting 30 days before the first dose of study vaccine(s)
             (HZ/su and/or FLU-D-QIV vaccines) and ending 30 days after the last dose of HZ/su
             vaccine.

          -  Administration of an influenza vaccine during the six months preceding entry into the
             study or planned administration up to the last blood sampling with the exception of
             the FLU-D-QIV vaccine given during this study.

          -  Administration of long-acting immune-modifying drugs (e.g. infliximab) within six
             months prior to the first vaccine dose or expected administration at any time during
             the study period.

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational vaccine/product (pharmaceutical product or device).

          -  Previous vaccination against VZV or HZ and/or planned administration during the study
             of a VZV or HZ vaccine (including an investigational or non-registered vaccine) other
             than the study vaccine.

          -  History of HZ.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition resulting
             from disease (e.g., malignancy, HIV infection) or immunosuppressive/cytotoxic therapy
             (e.g., medications used during cancer chemotherapy, organ transplantation or to treat
             autoimmune disorders).

          -  History of any reaction or hypersensitivity likely to be exacerbated by any component
             of the vaccines.

          -  History of Guillain Barré syndrome.

          -  Hypersensitivity to latex.

          -  Acute disease and/or fever at the time of enrolment.

               -  Fever is defined as temperature ≥ 37.5°C /99.5°F for oral, axillary or tympanic
                  route, or ≥ 38.0°C /100.4°F on rectal route. The preferred route for recording
                  temperature in this study will be oral.

               -  Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory
                  infection) without fever may, be enrolled at the discretion of the investigator.

          -  Administration of immunoglobulins and/or any blood products within the 3 months
             preceding the first dose of study vaccine or planned administration during the study
             period.

          -  Pregnant or lactating female.

          -  Female planning to become pregnant or planning to discontinue contraceptive
             precautions before 2 months after the last dose of study vaccine.

          -  Any condition which, in the opinion of the investigator, prevents the subject from
             participating in the study.

          -  Any condition which, in the judgment of the investigator would make intramuscular
             injection unsafe.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Carnegie</city>
        <state>Pennsylvania</state>
        <zip>15106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6T 0G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9W 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Weinheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>69469</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wuerzburg</city>
        <state>Bayern</state>
        <zip>97070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Floersheim</city>
        <state>Hessen</state>
        <zip>65439</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45355</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Goch</city>
        <state>Nordrhein-Westfalen</state>
        <zip>47574</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dippoldiswalde</city>
        <state>Sachsen</state>
        <zip>01744</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Freiberg</city>
        <state>Sachsen</state>
        <zip>09599</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Freital</city>
        <state>Sachsen</state>
        <zip>01705</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Luebeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23554</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10629</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10717</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13347</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>February 8, 2016</lastchanged_date>
  <firstreceived_date>September 19, 2013</firstreceived_date>
  <firstreceived_results_date>July 31, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FLU-D-QIV</keyword>
  <keyword>Adults</keyword>
  <keyword>Safety</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>co-administration</keyword>
  <keyword>Herpes zoster</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Out of the 829 subjects enrolled in this trial, 1 subject did not receive vaccination even though subject number had been allocated, hence he/she was excluded from study start.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GSK1437173A + GSK2321138A Group</title>
          <description>The subjects assigned to the Co-Ad group received one injection of the FLU-D-QIV vaccine and one injection of the HZ/su study vaccine during the first visit and a second injection of the HZ/su study vaccine during the third visit, two months later.</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>The subjects assigned to the Control group received all vaccines separately: one injection of the FLU-D-QIV vaccine at the first visit, one injection of the HZ/su study vaccine at the third visit and a second injection of the HZ/su study vaccine at the fourth visit, all two months apart.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="413"/>
                <participants group_id="P2" count="415"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="407"/>
                <participants group_id="P2" count="405"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GSK1437173A + GSK2321138A Group</title>
          <description>The subjects assigned to the Co-Ad group received one injection of the FLU-D-QIV vaccine and one injection of the HZ/su study vaccine during the first visit and a second injection of the HZ/su study vaccine during the third visit, two months later.</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>The subjects assigned to the Control group received all vaccines separately: one injection of the FLU-D-QIV vaccine at the first visit, one injection of the HZ/su study vaccine at the third visit and a second injection of the HZ/su study vaccine at the fourth visit, all two months apart.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="413"/>
                <measurement group_id="B2" value="415"/>
                <measurement group_id="B3" value="828"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="63.4" spread="8.3"/>
                <measurement group_id="B2" value="63.4" spread="8.8"/>
                <measurement group_id="B3" value="63.4" spread="8.55"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="211"/>
                <measurement group_id="B2" value="218"/>
                <measurement group_id="B3" value="429"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="202"/>
                <measurement group_id="B2" value="197"/>
                <measurement group_id="B3" value="399"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Vaccine Response to Anti-gE Antibodies</title>
        <description>The vaccine response(VRR) for anti-gE humoral immunogenicity, as determined by enzyme-linked immunosorbent assay (ELISA),was assessed only in subjects from the GSK1437173A + GSK2321138A Group. The VRR for anti-gE was defined as the percentage of subjects who had at least: a 4-fold increase in the post-dose 2 anti-gE antibody concentration as compared to the pre-vaccination anti-gE antibody concentration, for subjects who were seropositive at baseline (cut-off ≥ 97 mIU/ml), or, a 4-fold increase in the post dose 2 anti-gE antibody concentrations as compared to the anti-gE antibodies cut-off value for seropositivity, for subjects who were seronegative at baseline (cut-off &lt; 97 mIU/ml).</description>
        <time_frame>At one month post-dose 2 (Month 3)</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects (i.e. those meeting all eligibility criteria, complying with the procedures and intervals defined in the protocol, with no elimination criteria during the study) for whom data concerning immunogenicity outcome measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1437173A + GSK2321138A Group</title>
            <description>The subjects assigned to the Co-Ad group received one injection of the FLU-D-QIV vaccine and one injection of the HZ/su study vaccine during the first visit and a second injection of the HZ/su study vaccine during the third visit, two months later.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="382"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Vaccine Response to Anti-gE Antibodies</title>
            <description>The vaccine response(VRR) for anti-gE humoral immunogenicity, as determined by enzyme-linked immunosorbent assay (ELISA),was assessed only in subjects from the GSK1437173A + GSK2321138A Group. The VRR for anti-gE was defined as the percentage of subjects who had at least: a 4-fold increase in the post-dose 2 anti-gE antibody concentration as compared to the pre-vaccination anti-gE antibody concentration, for subjects who were seropositive at baseline (cut-off ≥ 97 mIU/ml), or, a 4-fold increase in the post dose 2 anti-gE antibody concentrations as compared to the anti-gE antibodies cut-off value for seropositivity, for subjects who were seronegative at baseline (cut-off &lt; 97 mIU/ml).</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="366"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vaccine Response for Anti-gE Humoral Immunogenicity</title>
        <description>The vaccine response(VRR) for anti-gE humoral immunogenicity, as determined by enzyme-linked immunosorbent assay (ELISA),was assessed only in subjects from the GSK1437173A + GSK2321138A Group. The VRR for anti-gE was defined as the percentage of subjects who had at least:
a 4-fold increase in the post-dose 2 anti-gE antibody concentration as compared to the pre-vaccination anti-gE antibody concentration, for subjects who were seropositive at baseline (cut-off ≥ 97 mIU/ml), or, a 4-fold increase in the post dose 2 anti-gE antibody concentrations as compared to the anti-gE antibodies cut-off value for seropositivity, for subjects who were seronegative at baseline (cut-off &lt; 97 mIU/ml).Criterion used: the objective was met if the Lower Limit (LL) of the 95% confidence interval (CI) of the VRR for anti-gE antibody concentrations was at least 60%.</description>
        <time_frame>At one month post-dose 2 (Month 3)</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects (i.e. those meeting all eligibility criteria, complying with the procedures and intervals defined in the protocol, with no elimination criteria during the study) for whom data concerning immunogenicity outcome measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1437173A + GSK2321138A Group</title>
            <description>The subjects assigned to the Co-Ad group received one injection of the FLU-D-QIV vaccine and one injection of the HZ/su study vaccine during the first visit and a second injection of the HZ/su study vaccine during the third visit, two months later.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="382"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Vaccine Response for Anti-gE Humoral Immunogenicity</title>
            <description>The vaccine response(VRR) for anti-gE humoral immunogenicity, as determined by enzyme-linked immunosorbent assay (ELISA),was assessed only in subjects from the GSK1437173A + GSK2321138A Group. The VRR for anti-gE was defined as the percentage of subjects who had at least:
a 4-fold increase in the post-dose 2 anti-gE antibody concentration as compared to the pre-vaccination anti-gE antibody concentration, for subjects who were seropositive at baseline (cut-off ≥ 97 mIU/ml), or, a 4-fold increase in the post dose 2 anti-gE antibody concentrations as compared to the anti-gE antibodies cut-off value for seropositivity, for subjects who were seronegative at baseline (cut-off &lt; 97 mIU/ml).Criterion used: the objective was met if the Lower Limit (LL) of the 95% confidence interval (CI) of the VRR for anti-gE antibody concentrations was at least 60%.</description>
            <units>Percentage</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="95.8" lower_limit="93.3" upper_limit="97.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adjusted Geometric Mean ELISA Concentrations of Anti-gE Antibodies</title>
        <description>Geometric means (GMs) of post-vaccination concentrations (Month 3 for GSK1437173A + GSK2321138A group and Month 5 for Control group) was calculated conditionally to the means of the pre-vaccination log-transformed concentrations for anti-gE (Month 0 for GSK1437173A + GSK2321138A group and Month 2 for Control group). Adjusted Least Squares (LS) means and difference of LS means between the groups were calculated together with 2-sided 95% CIs and back-transformed to the original units to provide GMCs.</description>
        <time_frame>At one month post-dose 2 (Month 3 for GSK1437173A + GSK2321138A group and Month 5 for Control group)</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects (i.e. those meeting all eligibility criteria, complying with the procedures and intervals defined in the protocol, with no elimination criteria during the study) for whom data concerning immunogenicity outcome measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1437173A + GSK2321138A Group</title>
            <description>The subjects assigned to the Co-Ad group received one injection of the FLU-D-QIV vaccine and one injection of the HZ/su study vaccine during the first visit and a second injection of the HZ/su study vaccine during the third visit, two months later.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>The subjects assigned to the Control group received all vaccines separately: one injection of the FLU-D-QIV vaccine at the first visit, one injection of the HZ/su study vaccine at the third visit and a second injection of the HZ/su study vaccine at the fourth visit, all two months apart.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="382"/>
                  <measurement group_id="O2" value="388"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Adjusted Geometric Mean ELISA Concentrations of Anti-gE Antibodies</title>
            <description>Geometric means (GMs) of post-vaccination concentrations (Month 3 for GSK1437173A + GSK2321138A group and Month 5 for Control group) was calculated conditionally to the means of the pre-vaccination log-transformed concentrations for anti-gE (Month 0 for GSK1437173A + GSK2321138A group and Month 2 for Control group). Adjusted Least Squares (LS) means and difference of LS means between the groups were calculated together with 2-sided 95% CIs and back-transformed to the original units to provide GMCs.</description>
            <units>mIU/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="52151.6" lower_limit="48356.0" upper_limit="56245.2"/>
                  <measurement group_id="O2" value="56247.4" lower_limit="52177.3" upper_limit="60634.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted ratios of Control group over GSK1437173A + GSK2321138A group in anti-gE antibody ELISA concentrations GMCs at one month after last vaccine dose. An Analysis of Covariance (ANCOVA) model was used to analyse post-vaccination log-transformed concentrations of anti-gE. The fixed-effect model included the minimisation variable (age cohorts) and the treatment as fixed effect. The pre-vaccination log-transformed concentrations were included as continuous covariate.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>Comparison at one month after the last dose of HZ/su was performed between the Control group and GSK1437173A + GSK2321138A group. The GSK1437173A + GSK2321138A group was considered as statistically significant non-inferior compared to the Control group in terms of immunogenicity if the UL of the 2-sided 95% CI of the ratio of GMs between the Control and the Co-Ad group (Control over GSK1437173A + GSK2321138A) was below 1.5.</non_inferiority_desc>
            <param_type>Adjusted Geometric mean concentration ra</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>FLU Haemagglutination Inhibition (HI) Antibodies Titers</title>
        <description>For each strain included in the FLU-D-QIV vaccine, an ANOVA model was used to analyze post-vaccination log-transformed titers. The fixed-effect model included the minimization variable (age cohorts) and the treatment as fixed effect. The pre-vaccination log-transformed concentrations were included as continuous covariate. Geometric Means (GM) of post-vaccination titers (Day 21) were calculated conditionally to the means of the pre-vaccination log-transformed titers (Month 0) for each strain.
Adjusted GMTs (GMTs adjusted for baseline titers) and Adjusted GMT ratios were calculated together with 2-sided 95% CIs.</description>
        <time_frame>At Day 21 post vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects (i.e. those meeting all eligibility criteria, complying with the procedures and intervals defined in the protocol, with no elimination criteria during the study) for whom data concerning immunogenicity outcome measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1437173A + GSK2321138A Group</title>
            <description>The subjects assigned to the Co-Ad group received one injection of the FLU-D-QIV vaccine and one injection of the HZ/su study vaccine during the first visit and a second injection of the HZ/su study vaccine during the third visit, two months later.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>The subjects assigned to the Control group received all vaccines separately: one injection of the FLU-D-QIV vaccine at the first visit, one injection of the HZ/su study vaccine at the third visit and a second injection of the HZ/su study vaccine at the fourth visit, all two months apart.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="384"/>
                  <measurement group_id="O2" value="394"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>FLU Haemagglutination Inhibition (HI) Antibodies Titers</title>
            <description>For each strain included in the FLU-D-QIV vaccine, an ANOVA model was used to analyze post-vaccination log-transformed titers. The fixed-effect model included the minimization variable (age cohorts) and the treatment as fixed effect. The pre-vaccination log-transformed concentrations were included as continuous covariate. Geometric Means (GM) of post-vaccination titers (Day 21) were calculated conditionally to the means of the pre-vaccination log-transformed titers (Month 0) for each strain.
Adjusted GMTs (GMTs adjusted for baseline titers) and Adjusted GMT ratios were calculated together with 2-sided 95% CIs.</description>
            <units>Titers</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Flu A/California/7/2009 H1N1 HI Day 21</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="187.5" lower_limit="166.7" upper_limit="210.8"/>
                  <measurement group_id="O2" value="194.3" lower_limit="173.0" upper_limit="218.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Flu A/Victoria/361/2011 H3N2 HI Day 21</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="84.1" lower_limit="76.5" upper_limit="92.4"/>
                  <measurement group_id="O2" value="89.6" lower_limit="81.6" upper_limit="98.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Flu B/Brisbane/60/2008 Victoria HI Day 21</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="177.2" lower_limit="156.1" upper_limit="185.6"/>
                  <measurement group_id="O2" value="181.6" lower_limit="166.7" upper_limit="197.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Flu B/Massachusetts/2/2012 Yamagata HI Day 21</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="423.5" lower_limit="392.0" upper_limit="457.5"/>
                  <measurement group_id="O2" value="413.9" lower_limit="383.4" upper_limit="446.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For the Flu A/California/7/2009 H1N1 strain ,an ANOVA model was used to analyze post-vaccination log-transformed titers. The fixed-effect model included the minimization variable (age cohorts) and the treatment as fixed effect. The pre-vaccination log-transformed concentrations were included as continuous covariate. GMs of post-vaccination titers (Day 21) were calculated conditionally to the means of the pre-vaccination log-transformed titers (Month 0) for this strain.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>Comparisons at Day 21 after the FLU-D-QIV dose were performed between the Control group and GSK1437173A + GSK2321138A group. The GSK1437173A + GSK2321138A group was considered as statistically significant non inferior compared to the Control group in terms of immunogenicity (for each strain) if the UL of 2-sided 95% CI of the ratio of GMTs between the Control and the GSK1437173A + GSK2321138A (Control/ GSK1437173A + GSK2321138A) group is below 1.5.</non_inferiority_desc>
            <param_type>Adjusted geometric mean Titer ratio</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For the Flu A/Victoria/361/2011 H3N2 strain ,an ANOVA model was used to analyze post-vaccination log-transformed titers. The fixed-effect model included the minimization variable (age cohorts) and the treatment as fixed effect. The pre-vaccination log-transformed concentrations were included as continuous covariate. GMs of post-vaccination titers (Day 21) were calculated conditionally to the means of the pre-vaccination log-transformed titers (Month 0) for this strain.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>Comparisons at Day 21 after the FLU-D-QIV dose were performed between the Control group and GSK1437173A + GSK2321138A group. The GSK1437173A + GSK2321138A group was considered as statistically significant non inferior compared to the Control group in terms of immunogenicity (for each strain) if the UL of 2-sided 95% CI of the ratio of GMTs between the Control and the GSK1437173A + GSK2321138A (Control/ GSK1437173A + GSK2321138A) group is below 1.5.</non_inferiority_desc>
            <param_type>Adjusted geometric mean Titer ratio</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For the Flu B/Brisbane/60/2008 Victoria strain ,an ANOVA model was used to analyze post-vaccination log-transformed titers. The fixed-effect model included the minimization variable (age cohorts) and the treatment as fixed effect. The pre-vaccination log-transformed concentrations were included as continuous covariate. GMs of post-vaccination titers (Day 21) were calculated conditionally to the means of the pre-vaccination log-transformed titers (Month 0) for this strain.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>Comparisons at Day 21 after the FLU-D-QIV dose were performed between the Control group and GSK1437173A + GSK2321138A group. The GSK1437173A + GSK2321138A group was considered as statistically significant non inferior compared to the Control group in terms of immunogenicity (for each strain) if the UL of 2-sided 95% CI of the ratio of GMTs between the Control and the GSK1437173A + GSK2321138A (Control/ GSK1437173A + GSK2321138A) group is below 1.5.</non_inferiority_desc>
            <param_type>Adjusted geometric mean Titer ratio</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For the Flu B/Massachusetts/2/2012 Yamagata strain ,an ANOVA model was used to analyze post-vaccination log-transformed titers. The fixed-effect model included the minimization variable (age cohorts) and the treatment as fixed effect. The pre-vaccination log-transformed concentrations were included as continuous covariate. GMs of post-vaccination titers (Day 21) were calculated conditionally to the means of the pre-vaccination log-transformed titers (Month 0) for this strain.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>Comparisons at Day 21 after the FLU-D-QIV dose were performed between the Control group and GSK1437173A + GSK2321138A group. The GSK1437173A + GSK2321138A group was considered as statistically significant non inferior compared to the Control group in terms of immunogenicity (for each strain) if the UL of 2-sided 95% CI of the ratio of GMTs between the Control and the GSK1437173A + GSK2321138A (Control/ GSK1437173A + GSK2321138A) group is below 1.5.</non_inferiority_desc>
            <param_type>Adjusted geometric mean Titer ratio</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With FLU HI Antibodies ≥1:10</title>
        <description>FLU HI antibodies were assessed in four strains: Flu A/California/7/2009 H1N1, Flu A/Victoria/361/2011 H3N2, Flu B/Brisbane/60/2008 Victoria and Flu B/Massachusetts/2/2012 Yamagata (Yamag). Cut-off titer for seropositivity was 1:10.</description>
        <time_frame>At Days 0 and 21 post vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects (i.e. those meeting all eligibility criteria, complying with the procedures and intervals defined in the protocol, with no elimination criteria during the study) for whom data concerning immunogenicity outcome measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1437173A + GSK2321138A Group</title>
            <description>The subjects assigned to the Co-Ad group received one injection of the FLU-D-QIV vaccine and one injection of the HZ/su study vaccine during the first visit and a second injection of the HZ/su study vaccine during the third visit, two months later.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>The subjects assigned to the Control group received all vaccines separately: one injection of the FLU-D-QIV vaccine at the first visit, one injection of the HZ/su study vaccine at the third visit and a second injection of the HZ/su study vaccine at the fourth visit, all two months apart.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="386"/>
                  <measurement group_id="O2" value="395"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With FLU HI Antibodies ≥1:10</title>
            <description>FLU HI antibodies were assessed in four strains: Flu A/California/7/2009 H1N1, Flu A/Victoria/361/2011 H3N2, Flu B/Brisbane/60/2008 Victoria and Flu B/Massachusetts/2/2012 Yamagata (Yamag). Cut-off titer for seropositivity was 1:10.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Flu A/California/7/2009 H1N1 Day 0 [N=386,395]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="288"/>
                  <measurement group_id="O2" value="294"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Flu A/California/7/2009 H1N1Day 21 [N=384,394]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="381"/>
                  <measurement group_id="O2" value="389"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Flu A/Victoria/361/2011 H3N2 Day 0 [N=386,395]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="311"/>
                  <measurement group_id="O2" value="326"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Flu A/Victoria/361/2011 H3N2 Day 21 [N=384,394]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="381"/>
                  <measurement group_id="O2" value="393"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Flu B/Brisbane/60/2008 Victoria Day 0 [N=386,395]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="365"/>
                  <measurement group_id="O2" value="375"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Flu B/Brisbane/60/2008 Victoria Day 21 [N=384,394]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="383"/>
                  <measurement group_id="O2" value="394"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Flu B/Massachusetts/2/2012 Yamag Day 0 [N=386,395]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="376"/>
                  <measurement group_id="O2" value="389"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Flu B/Massachusetts/2/2012 Yamag Day21 [N=384,394]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="384"/>
                  <measurement group_id="O2" value="394"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected Subjects With HI Antibody Concentrations ≥ 1:40</title>
        <description>Seroprotection rate is defined as the percentage of vaccines with a serum HI titer ≥1:40 that usually was accepted as indicating protection.</description>
        <time_frame>At Day 0 (PRE) and at Day 21 post vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects (i.e. those meeting all eligibility criteria, complying with the procedures and intervals defined in the protocol, with no elimination criteria during the study) for whom data concerning immunogenicity outcome measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1437173A + GSK2321138A Group</title>
            <description>The subjects assigned to the Co-Ad group received one injection of the FLU-D-QIV vaccine and one injection of the HZ/su study vaccine during the first visit and a second injection of the HZ/su study vaccine during the third visit, two months later.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>The subjects assigned to the Control group received all vaccines separately: one injection of the FLU-D-QIV vaccine at the first visit, one injection of the HZ/su study vaccine at the third visit and a second injection of the HZ/su study vaccine at the fourth visit, all two months apart.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="386"/>
                  <measurement group_id="O2" value="395"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seroprotected Subjects With HI Antibody Concentrations ≥ 1:40</title>
            <description>Seroprotection rate is defined as the percentage of vaccines with a serum HI titer ≥1:40 that usually was accepted as indicating protection.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Flu A/California/7/2009 H1N1 HI Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="185"/>
                  <measurement group_id="O2" value="161"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Flu A/California/7/2009 H1N1 HI Day 21</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="347"/>
                  <measurement group_id="O2" value="360"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Flu A/Victoria/361/2011 H3N2 HI Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="156"/>
                  <measurement group_id="O2" value="157"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Flu A/Victoria/361/2011 H3N2 HI Day 21</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="320"/>
                  <measurement group_id="O2" value="326"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Flu B/Brisbane/60/2008 Victoria HI Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="279"/>
                  <measurement group_id="O2" value="271"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Flu B/Brisbane/60/2008 Victoria HI Day 21</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="372"/>
                  <measurement group_id="O2" value="382"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Flu B/Massachusetts/2/2012 Yamagata HI Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="351"/>
                  <measurement group_id="O2" value="361"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Flu B/Massachusetts/2/2012 Yamagata HI Day 21</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="383"/>
                  <measurement group_id="O2" value="393"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FLU Haemagglutination Inhibition (HI) Antibody Titers</title>
        <description>HI antibody titres against the four influenza vaccine strains Flu A/California/7/2009, Flu A/Victoria/361/2011, Flu B/Brisbane/60/2008 Victoria and Flu B/Massachusetts/2/2012 Yamagata were expressed as geometric mean titers (GMTs).</description>
        <time_frame>At Day 0 (PRE) and Day 21 post vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects (i.e. those meeting all eligibility criteria, complying with the procedures and intervals defined in the protocol, with no elimination criteria during the study) for whom data concerning immunogenicity outcome measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1437173A + GSK2321138A Group</title>
            <description>The subjects assigned to the Co-Ad group received one injection of the FLU-D-QIV vaccine and one injection of the HZ/su study vaccine during the first visit and a second injection of the HZ/su study vaccine during the third visit, two months later.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>The subjects assigned to the Control group received all vaccines separately: one injection of the FLU-D-QIV vaccine at the first visit, one injection of the HZ/su study vaccine at the third visit and a second injection of the HZ/su study vaccine at the fourth visit, all two months apart.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="386"/>
                  <measurement group_id="O2" value="395"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>FLU Haemagglutination Inhibition (HI) Antibody Titers</title>
            <description>HI antibody titres against the four influenza vaccine strains Flu A/California/7/2009, Flu A/Victoria/361/2011, Flu B/Brisbane/60/2008 Victoria and Flu B/Massachusetts/2/2012 Yamagata were expressed as geometric mean titers (GMTs).</description>
            <units>Titers</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Flu A/California/7/2009 H1N1 HI Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29" lower_limit="25.1" upper_limit="33.5"/>
                  <measurement group_id="O2" value="24.9" lower_limit="21.8" upper_limit="28.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Flu A/California/7/2009 H1N1 HI Day 21</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="196.2" lower_limit="172.2" upper_limit="223.5"/>
                  <measurement group_id="O2" value="193.2" lower_limit="170.2" upper_limit="219.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Flu A/Victoria/361/2011 H3N2 HI Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23.7" lower_limit="21" upper_limit="26.8"/>
                  <measurement group_id="O2" value="23.4" lower_limit="20.8" upper_limit="26.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Flu A/Victoria/361/2011 H3N2 HI Day 21</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="86.3" lower_limit="77.1" upper_limit="96.5"/>
                  <measurement group_id="O2" value="91.4" lower_limit="81.9" upper_limit="102"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Flu B/Brisbane/60/2008 Victoria HI Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52.2" lower_limit="46.9" upper_limit="58.1"/>
                  <measurement group_id="O2" value="48.6" lower_limit="43.7" upper_limit="54"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Flu B/Brisbane/60/2008 Victoria HI Day 21</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="177.2" lower_limit="161.6" upper_limit="194.2"/>
                  <measurement group_id="O2" value="185.2" lower_limit="168" upper_limit="204.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Flu B/Massachusetts/2/2012 Yamagata HI Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="128.8" lower_limit="115.7" upper_limit="143.4"/>
                  <measurement group_id="O2" value="127" lower_limit="114.9" upper_limit="140.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Flu B/Massachusetts/2/2012 Yamagata HI Day 21</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="433.7" lower_limit="401.3" upper_limit="468.7"/>
                  <measurement group_id="O2" value="423.3" lower_limit="388" upper_limit="461.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroconverted Subjects in Terms of HI Antibodies</title>
        <description>The number of seroconverted subjects was assessed in terms of HI antibodies against the four influenza vaccine strains Flu A/California/7/2009, Flu A/Victoria/361/2011, Flu B/Brisbane/60/2008 Victoria and Flu B/Massachusetts/2/2012 Yamagata.</description>
        <time_frame>At Day 21 post vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects (i.e. those meeting all eligibility criteria, complying with the procedures and intervals defined in the protocol, with no elimination criteria during the study) for whom data concerning immunogenicity outcome measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1437173A + GSK2321138A Group</title>
            <description>The subjects assigned to the Co-Ad group received one injection of the FLU-D-QIV vaccine and one injection of the HZ/su study vaccine during the first visit and a second injection of the HZ/su study vaccine during the third visit, two months later.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>The subjects assigned to the Control group received all vaccines separately: one injection of the FLU-D-QIV vaccine at the first visit, one injection of the HZ/su study vaccine at the third visit and a second injection of the HZ/su study vaccine at the fourth visit, all two months apart.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="384"/>
                  <measurement group_id="O2" value="394"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seroconverted Subjects in Terms of HI Antibodies</title>
            <description>The number of seroconverted subjects was assessed in terms of HI antibodies against the four influenza vaccine strains Flu A/California/7/2009, Flu A/Victoria/361/2011, Flu B/Brisbane/60/2008 Victoria and Flu B/Massachusetts/2/2012 Yamagata.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Flu A/California/7/2009 H1N1 HI</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="232"/>
                  <measurement group_id="O2" value="240"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Flu A/Victoria/361/2011 H3N2 HI</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="159"/>
                  <measurement group_id="O2" value="162"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Flu B/Brisbane/60/2008 Victoria HI</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="143"/>
                  <measurement group_id="O2" value="169"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Flu B/Massachusetts/2/2012 Yamagata HI</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="154"/>
                  <measurement group_id="O2" value="148"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Ratio for Flu HI Antibodies Post-vaccination Titer</title>
        <description>The geometric mean ratio for Flu HI antibodies against the four influenza vaccine strains Flu A/California/7/2009, Flu A/Victoria/361/2011, Flu B/Brisbane/60/2008 Victoria and Flu B/Massachusetts/2/2012 Yamagata was defined as the geometric mean of the within subject ratios of the post-vaccination reciprocal HI titer to the Day 0 reciprocal HI titer.</description>
        <time_frame>At Day 21 post vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects (i.e. those meeting all eligibility criteria, complying with the procedures and intervals defined in the protocol, with no elimination criteria during the study) for whom data concerning immunogenicity outcome measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1437173A + GSK2321138A Group</title>
            <description>The subjects assigned to the Co-Ad group received one injection of the FLU-D-QIV vaccine and one injection of the HZ/su study vaccine during the first visit and a second injection of the HZ/su study vaccine during the third visit, two months later.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>The subjects assigned to the Control group received all vaccines separately: one injection of the FLU-D-QIV vaccine at the first visit, one injection of the HZ/su study vaccine at the third visit and a second injection of the HZ/su study vaccine at the fourth visit, all two months apart.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="384"/>
                  <measurement group_id="O2" value="394"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Geometric Mean Ratio for Flu HI Antibodies Post-vaccination Titer</title>
            <description>The geometric mean ratio for Flu HI antibodies against the four influenza vaccine strains Flu A/California/7/2009, Flu A/Victoria/361/2011, Flu B/Brisbane/60/2008 Victoria and Flu B/Massachusetts/2/2012 Yamagata was defined as the geometric mean of the within subject ratios of the post-vaccination reciprocal HI titer to the Day 0 reciprocal HI titer.</description>
            <units>Ratio</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Flu A/California/7/2009 H1N1 HI</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.8" lower_limit="5.9" upper_limit="7.8"/>
                  <measurement group_id="O2" value="7.7" lower_limit="6.7" upper_limit="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Flu A/Victoria/361/2011 H3N2 HI</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.6" lower_limit="3.3" upper_limit="4.1"/>
                  <measurement group_id="O2" value="3.9" lower_limit="3.5" upper_limit="4.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Flu B/Brisbane/60/2008 Victoria HI</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.4" lower_limit="3" upper_limit="3.8"/>
                  <measurement group_id="O2" value="3.8" lower_limit="3.4" upper_limit="4.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Flu B/Massachusetts/2/2012 Yamagata HI</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.4" lower_limit="3" upper_limit="3.7"/>
                  <measurement group_id="O2" value="3.3" lower_limit="3" upper_limit="3.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Solicited Local Symptoms</title>
        <description>Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. Relationship analysis was not performed.</description>
        <time_frame>Within 7 days (Days 0-6) after each vaccine dose</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects with at least one study vaccine administered, on subjects with their symptom sheets completed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1437173A + GSK2321138A Group</title>
            <description>The subjects assigned to the Co-Ad group received one injection of the FLU-D-QIV vaccine and one injection of the HZ/su study vaccine during the first visit and a second injection of the HZ/su study vaccine during the third visit, two months later.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="410"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Solicited Local Symptoms</title>
            <description>Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. Relationship analysis was not performed.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any Pain Dose 1 [N=410;412]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="308"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Pain Dose 1 [N=410;412]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="36"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Redness Dose 1 [N=410;412]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="124"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Redness Dose 1 [N=410;412]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Swelling Dose 1 [N=410;412]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="71"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Swelling Dose 1 [N=410;412]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Pain Dose 2 [N=403;405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="290"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Pain Dose 2 [N=403;405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Redness Dose 2 [N=403;405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="103"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Redness Dose 2 [N=403;405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Swelling Dose 2 [N=403;405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="64"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Swelling Dose 2 [N=403;405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Solicited Local Symptoms</title>
        <description>Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. Relationship analysis was not performed</description>
        <time_frame>Within 7 days (Days 0-6) after each vaccine dose</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects with at least one study vaccine administered, on subjects with their symptom sheets completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>The subjects assigned to the Control group received all vaccines separately: one injection of the FLU-D-QIV vaccine at the first visit, one injection of the HZ/su study vaccine at the third visit and a second injection of the HZ/su study vaccine at the fourth visit, all two months apart.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="402"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Solicited Local Symptoms</title>
            <description>Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. Relationship analysis was not performed</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any Pain, Dose 1 [N=412]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="112"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Pain, Dose 1 [N=412]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Redness, Dose 1 [N=412]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="37"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Redness, Dose 1 [N=412]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Swelling, Dose 1 [N=412]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Swelling, Dose 1 [N=412]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Pain, Dose 2 [N=405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="280"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Pain, Dose 2 [N=405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Redness, Dose 2 [N=405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="91"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Redness, Dose 2 [N=405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Swelling, Dose 2 [N=405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Swelling, Dose 2 [N=405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Pain, Dose 3 [N=402]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="269"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Pain, Dose 3 [N=402]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Redness, Dose 3 [N=402]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Redness, Dose 3 [N=402]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Swelling, Dose 3 [N=402]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Swelling, Dose 3 [N=402]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Solicited General Symptoms</title>
        <description>Assessed solicited general symptoms were arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.</description>
        <time_frame>Within 7 days (Days 0-6) after each vaccine dose</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects with at least one study vaccine administered, on subjects with their symptom sheets completed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1437173A + GSK2321138A Group</title>
            <description>The subjects assigned to the Co-Ad group received one injection of the FLU-D-QIV vaccine and one injection of the HZ/su study vaccine during the first visit and a second injection of the HZ/su study vaccine during the third visit, two months later.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="409"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Solicited General Symptoms</title>
            <description>Assessed solicited general symptoms were arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any Arthralgia Dose 1 [N=409;411]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="89"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Arthralgia Dose 1 [N=409;411]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Arthralgia Dose 1 [N=409;411]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="67"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Fatigue Dose 1 [N=409;411]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="150"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Fatigue Dose 1 [N=409;411]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Fatigue Dose 1 [N=409;411]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="107"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Gastrointestinal Dose 1 [N=409;411]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="57"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Gastrointestinal Dose 1 [N=409;411]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Headache Dose 1 [N=409;411]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Headache Dose 1 [N=409;411]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="122"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Headache Dose 1 [N=409;411]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Headache Dose 1 [N=409;411]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="80"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Myalgia Dose 1 [N=409;411]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="135"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Myalgia Dose 1 [N=409;411]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Myalgia Dose 1 [N=409;411]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="105"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Shivering Dose 1 [N=409;411]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="101"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Shivering Dose 1 [N=409;411]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Shivering Dose 1 [N=409;411]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="86"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Temperature Dose 1 [N=409;411]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="63"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Temperature Dose 1 [N=409;411]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Temperature Dose 1 [N=409;411]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="53"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Arthralgia Dose 2 [N=402;405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="114"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Arthralgia Dose 2 [N=402;405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Arthralgia Dose 2 [N=402;405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="94"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Fatigue Dose 2 [N=402;405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="167"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Fatigue Dose 2 [N=402;405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Fatigue Dose 2 [N=402;405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="138"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Gastrointestinal Dose 2 [N=402;405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Gastrointestinal Dose 2 [N=402;405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Gastrointestinal Dose 2 [N=402;405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Headache Dose 2 [N=402;405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="136"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Headache Dose 2 [N=402;405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Headache Dose 2 [N=402;405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="109"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Myalgia Dose 2 [N=402;405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Myalgia Dose 2 [N=402;405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="135"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Shivering Dose 2 [N=402;405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="142"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Shivering Dose 2 [N=402;405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Shivering Dose 2 [N=402;405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="122"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Temperature Dose 2 [N=402;405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="74"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Temperature Dose 2 [N=402;405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Temperature Dose 2 [N=402;405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="63"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Myalgia Dose 2 [N=402;405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="157"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Solicited General Symptoms</title>
        <description>Assessed solicited general symptoms were arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.</description>
        <time_frame>Within 7 days (Days 0-6) after each vaccine dose</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects with at least one study vaccine administered, on subjects with their symptom sheets completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>The subjects assigned to the Control group received all vaccines separately: one injection of the FLU-D-QIV vaccine at the first visit, one injection of the HZ/su study vaccine at the third visit and a second injection of the HZ/su study vaccine at the fourth visit, all two months apart.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="402"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Solicited General Symptoms</title>
            <description>Assessed solicited general symptoms were arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any Arthralgia, Dose 1 [N=411]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="37"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Arthralgia, Dose 1 [N=411]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Arthralgia, Dose 1 [N=411]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Fatigue, Dose 1 [N=411]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Fatigue, Dose 1 [N=411]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Fatigue, Dose 1 [N=411]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Gastrointestinal, Dose 1 [N=411]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Gastrointestinal, Dose 1 [N=411]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Gastrointestinal, Dose 1 [N=411]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Headache, Dose 1 [N=411]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="57"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Headache, Dose 1 [N=411]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Headache, Dose 1 [N=411]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="31"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Myalgia, Dose 1 [N=411]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="55"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Myalgia, Dose 1 [N=411]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Myalgia, Dose 1 [N=411]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="45"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Shivering, Dose 1 [N=411]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Shivering, Dose 1 [N=411]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Shivering, Dose 1 [N=411]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Temperature, Dose 1 [N=411]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Temperature, Dose 1 [N=411]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Temperature, Dose 1 [N=411]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Arthralgia, Dose 2 [N=405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="67"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Arthralgia, Dose 2 [N=405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Arthralgia, Dose 2 [N=405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="51"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Fatigue, Dose 2 [N=405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="108"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Fatigue, Dose 2 [N=405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Fatigue, Dose 2 [N=405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="87"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Gastrointestinal, Dose 2 [N=405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="36"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Gastrointestinal, Dose 2 [N=405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Gastrointestinal, Dose 2 [N=405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Headache, Dose 2 [N=405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="87"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Headache, Dose 2 [N=405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Headache, Dose 2 [N=405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="70"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Myalgia, Dose 2 [N=405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="135"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Myalgia, Dose 2 [N=405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Myalgia, Dose 2 [N=405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="115"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Shivering, Dose 2 [N=405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="87"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Shivering, Dose 2 [N=405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Shivering, Dose 2 [N=405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="75"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Temperature, Dose 2 [N=405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="44"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Temperature, Dose 2 [N=405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Temperature, Dose 2 [N=405]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Arthralgia, Dose 3 [N=402]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="95"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Arthralgia, Dose 3 [N=402]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Arthralgia, Dose 3 [N=402]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="79"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Fatigue, Dose 3 [N=402]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="149"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Fatigue, Dose 3 [N=402]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="31"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Fatigue, Dose 3 [N=402]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="120"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Gastrointestinal, Dose 3 [N=402]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="62"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Gastrointestinal, Dose 3 [N=402]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Gastrointestinal, Dose 3 [N=402]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Headache, Dose 3 [N=402]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="133"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Headache, Dose 3 [N=402]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Headache, Dose 3 [N=402]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="111"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Myalgia, Dose 3 [N=402]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="138"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Myalgia, Dose 3 [N=402]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Myalgia, Dose 3 [N=402]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="121"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Shivering, Dose 3 [N=402]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="147"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Shivering, Dose 3 [N=402]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Shivering, Dose 3 [N=402]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="131"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Temperature, Dose 3 [N=402]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="87"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Temperature, Dose 3 [N=402]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Temperature, Dose 3 [N=402]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="70"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Unsolicited Adverse Events (AEs)</title>
        <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.</description>
        <time_frame>During 30 days (Days 0-29) after vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects with at least one study vaccine administered.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1437173A + GSK2321138A Group</title>
            <description>The subjects assigned to the Co-Ad group received one injection of the FLU-D-QIV vaccine and one injection of the HZ/su study vaccine during the first visit and a second injection of the HZ/su study vaccine during the third visit, two months later.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>The subjects assigned to the Control group received all vaccines separately: one injection of the FLU-D-QIV vaccine at the first visit, one injection of the HZ/su study vaccine at the third visit and a second injection of the HZ/su study vaccine at the fourth visit, all two months apart.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="413"/>
                  <measurement group_id="O2" value="415"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Unsolicited Adverse Events (AEs)</title>
            <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any AEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="110"/>
                  <measurement group_id="O2" value="162"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 AEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="30"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related AEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
        <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
        <time_frame>From first vaccination up to Month 18 (study end)</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects with at least one study vaccine administered.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1437173A + GSK2321138A Group</title>
            <description>The subjects assigned to the Co-Ad group received one injection of the FLU-D-QIV vaccine and one injection of the HZ/su study vaccine during the first visit and a second injection of the HZ/su study vaccine during the third visit, two months later.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>The subjects assigned to the Control group received all vaccines separately: one injection of the FLU-D-QIV vaccine at the first visit, one injection of the HZ/su study vaccine at the third visit and a second injection of the HZ/su study vaccine at the fourth visit, all two months apart.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="413"/>
                  <measurement group_id="O2" value="415"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
            <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="41"/>
                  <measurement group_id="O2" value="40"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Potential Immune-mediated Diseases (pIMDs)</title>
        <description>pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.</description>
        <time_frame>From first vaccination up to Month 18 (study end)</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects with at least one study vaccine administered.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1437173A + GSK2321138A Group</title>
            <description>The subjects assigned to the Co-Ad group received one injection of the FLU-D-QIV vaccine and one injection of the HZ/su study vaccine during the first visit and a second injection of the HZ/su study vaccine during the third visit, two months later.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>The subjects assigned to the Control group received all vaccines separately: one injection of the FLU-D-QIV vaccine at the first visit, one injection of the HZ/su study vaccine at the third visit and a second injection of the HZ/su study vaccine at the fourth visit, all two months apart.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="413"/>
                  <measurement group_id="O2" value="415"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Potential Immune-mediated Diseases (pIMDs)</title>
            <description>pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Systematically-assessed symptoms: Days 0-7 post each vaccine dose; AEs: Days 0-29 post each vaccine dose; SAEs: from Day 0 to Month 18</time_frame>
      <group_list>
        <group group_id="E1">
          <title>GSK1437173A + GSK2321138A Group</title>
          <description>The subjects assigned to the Co-Ad group received one injection of the FLU-D-QIV vaccine and one injection of the HZ/su study vaccine during the first visit and a second injection of the HZ/su study vaccine during the third visit, two months later.</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>The subjects assigned to the Control group received all vaccines separately: one injection of the FLU-D-QIV vaccine at the first visit, one injection of the HZ/su study vaccine at the third visit and a second injection of the HZ/su study vaccine at the fourth visit, all two months apart.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypochromic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Vestibular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Death (unknown causes)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Breast cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Cellulitis pharyngeal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Traumatic lung injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Adrenal adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Hepatic cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Acquired syringomyelia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Occipital neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus urethral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="308" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="280" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="308" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="280" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="124" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="114" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="167" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="149" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="136" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="133" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="157" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="138" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Shivering</sub_title>
                <counts group_id="E1" subjects_affected="142" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="147" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Temperature/(Oral)</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
